Bulk order Acrobiosystems for Chinese

Chinese

A-Z

SARS-CoV-2 | CD24 | CD73 | Trimer | CD19 | PD-1

There is no goods in the shopping cart !

My Cart

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Home
Product & Service

Products by Category

Recombinant proteins and more
FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew Biosimilar Drug TargetsHot Tumor MicroenvironmentHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins
Services

Innovation Lab ServicesNew SPR /BLI analytical serviceNew

Pre-labeled proteins
Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew Universal ELISA KitsNew ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum SamplesNew Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis CD24 & Siglec-10 proteinsHot

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew SARS-CoV-2 spike mutantsNew
Others
Bispecific antibody targetsHot Targets for ADCsHot IL-2 ReceptorsHot CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot B7 family proteinsHot TNFSF proteinsHot VEGF proteinsHot CD39/CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive PD1 proteinsHot
Support

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Application

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
X-LAB
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

Your Position: Home > ICOS

ICOS

ICOS Molecule Information

Name:Inducible T-cell costimulator
Target Synonym:Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein,Activation-inducible lymphocyte immunomediatory molecule

Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 3 Clinical

ICOS Protein Product ListCompare or Buy

Product> Filter Results

Cat. No.	Species	Product Description
ICS-M5259	Mouse	Mouse ICOS / CD278 (C137S, C138S) Protein, Fc Tag
ICS-M52H8	Mouse	Mouse ICOS / CD278 (C137S, C138S) Protein, His Tag
ICS-H5258	Human	Human ICOS / CD278 Protein, Fc Tag
ICS-H82E5	Human	Biotinylated Human ICOS / CD278 (C136S, C137S) Protein, His,Avitag™ (recommended for biopanning)
ICS-H52H6	Human	Human ICOS / CD278 (C136S, C137S) Protein, His Tag

ICOS Part of Bioactivity data

ICS-M52H8-ELISA

Immobilized Human B7-H2, Fc Tag (Cat. No. B72-H5254) at 5 μg/mL (100 μL/well) can bind Mouse ICOS (C137S, C138S), His Tag (Cat. No. ICS-M52H8) with a linear range of 39-625 ng/mL (QC tested).

Protocol

ICS-M5259-ELISA

Immobilized Human B7-H2, His Tag (Cat. No. B72-H5221) at 1 μg/mL (100 μL/well) can bind Mouse ICOS (C137S, C138S), Fc Tag (Cat. No. ICS-M5259) with a linear range of 0.3-10 ng/mL (QC tested).

Protocol

ICOS Molecule Synonym Name

ICOS,CD278,AILIM,Inducible T-cell costimulator

ICOS Molecule Background

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS References

ICOS Related Molecule

B7-H2

ICOS Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
KY-1044	KY-1044	Phase 2 Clinical	Kymab	Liver Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular	Details
ALPN-101	ALPN-101	Phase 1 Clinical	Alpine Immune Sciences	Graft vs Host Disease; Autoimmune Diseases; Lymphoproliferative Disorders; Inflammation	Details
Anti-ICOS (Bristol Myers Squibb)	BMS-986226	Phase 1 Clinical	Bristol-Myers Squibb Company	Neoplasms	Details
Vopratelimab	JTX-2011	Phase 2 Clinical	Jounce Therapeutics	Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung	Details
XmAb-23104 (Xencor)		Phase 1 Clinical	Xencor	Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Sarcoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms	Details
GSK-3359609	GSK-3359609	Phase 3 Clinical	Glaxosmithkline Plc	Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma	Details